Ovid Therapeutics Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging -2.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.10 | $-0.08 | +20.0% | Beat | |
| Q1 FY26 | $-0.12 | $-0.12 | +0.0% | Beat | |
| Q4 FY25 | not reported | $0.06 | not reported | not reported | |
| Q3 FY25 | $-0.15 | $-0.17 | -13.3% | Miss | |
| Q2 FY25 | not reported | $-0.06 | not reported | not reported | |
| Q1 FY25 | $-0.14 | $-0.14 | +0.0% | Beat | |
| Q4 FY24 | $-0.16 | $-0.13 | +18.8% | Beat | |
| Q3 FY24 | $-0.19 | $-0.20 | -5.3% | Miss | |
| Q2 FY24 | not reported | $0.12 | not reported | not reported | |
| Q1 FY24 | $-0.23 | $-0.17 | +26.1% | Beat | |
| Q4 FY23 | $-0.17 | $-0.22 | -29.4% | Miss | |
| Q3 FY23 | $-0.18 | $-0.16 | +11.1% | Beat |
Back to OVID overview · OVID holders · OVID KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.